行情

SYRS

SYRS

Syros Pharms
NASDAQ

实时行情|Nasdaq Last Sale

4.600
-0.040
-0.86%
盘后: 4.575 -0.025 -0.54% 16:00 12/06 EST
开盘
4.650
昨收
4.640
最高
4.740
最低
4.550
成交量
19.01万
成交额
--
52周最高
11.93
52周最低
4.530
市值
1.95亿
市盈率(TTM)
-2.3521
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SYRS 新闻

  • Edited Transcript of SYRS earnings conference call or presentation 12-Nov-19 1:30pm GMT
  • Thomson Reuters StreetEvents.3天前
  • 意大利最大商业银行拟裁员8000人
  • 新浪财经.3天前
  • 意大利总理支持欧洲稳定机制改革 遭反对党批评
  • 中国新闻网.3天前
  • 韩2019网购销售额破100万亿韩元 披萨炸鸡交易额剧增
  • 中国新闻网.3天前

更多

所属板块

制药
+0.53%
制药与医学研究
+0.68%

热门股票

名称
价格
涨跌幅

SYRS 简况

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company's drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, solid tumors, inflammatory diseases and other diseases to find optimal points of therapeutic intervention in patients.
展开

Webull提供Syros Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。